FORTE trial: Impact of minimal residual disease on multiple myeloma patients

Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study

ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma

Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma

Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in newly diagnosed or R/R AML

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL

Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol

Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study

Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves survival in children with T-LL

Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia

ecancer special issue on immunotherapy